A. Banzato

Clinical course of high‐risk patients diagnosed with antiphospholipid syndrome

Vittorio Pengo, Amelia Ruffatti, Cristina Legnani et al. · Journal of Thrombosis and Haemostasis · 2009 · 619 citations · Full text

Medicine, Hematology, Internal Medicine +12

Antiphospholipid syndrome: antibodies to Domain 1 of β2‐glycoprotein 1 correctly classify patients at risk

Vittorio Pengo, Amelia Ruffatti, Marta Tonello et al. · Journal of Thrombosis and Haemostasis · 2015 · 125 citations

Life Sciences, Hematology, Immunology +14

Effectiveness of fixed minidose warfarin in the prevention of thromboembolism and vascular death in nonrheumatic atrial fibrillation∗∗The investigators and institutions participating in the study are listed in the Appendix.

Vittorio Pengo, Antonella Zasso, Fabio Barbero et al. · The American Journal of Cardiology · 1998 · 109 citations

Medicine, Pharmacology, Pharmacotherapy +13

Confirmation of initial antiphospholipid antibody positivity depends on the antiphospholipid antibody profile

Vittorio Pengo, Amelia Ruffatti, T. Del Ross et al. · Journal of Thrombosis and Haemostasis · 2013 · 100 citations · Full text

Life Sciences, Hematology, Immunology +12

Efficacy and safety of rivaroxaban vs warfarin in high-risk patients with antiphospholipid syndrome: Rationale and design of the Trial on Rivaroxaban in AntiPhospholipid Syndrome (TRAPS) trial

Vittorio Pengo, A. Banzato, Elisa Bison et al. · Lupus · 2015 · 87 citations

Medicine, Pharmacology, Pharmacotherapy +17